NCT05363111View on ClinicalTrials.gov

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 22, 2022

Primary Completion Date

February 24, 2026

Study Completion Date

February 24, 2026

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
BIOLOGICAL

Actinium Ac 225-DOTA-Daratumumab

Given IV

BIOLOGICAL

Daratumumab

Given IV

BIOLOGICAL

Indium In 111-DOTA-Daratumumab

Given IV

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER